|[December 04, 2012]
ChemoFx® Used to Develop Multi-Gene Predictors to Chemotherapy in Breast Cancer
PITTSBURGH --(Business Wire)--
Precision Therapeutics recently conducted two studies that evaluate cell
line derived Multi-Gene Predictors of pathologic response to neoadjuvant
chemotherapy in breast cancer.
Cell Line Derived Multi-Gene Predictor of Pathologic Response to
Neoadjuvant Chemotherapy in Breast Cancer: A Validation Study on US
Oncology 02-103 Clinical Trial assesses the predictive accuracy of a
multi-gene predictor to four commonly used chemotherapies in breast
cancer patients. The MGP was developed from a panel of 42 breast cancer
cell-lines treated with the 4-drug combination in vitro and was
evaluated for predictive ability on patient samples obtained during a
prospective neoadjuvant clinical trial.
An independent validation performed by MD Anderson Cancer Center on
patients from the US Oncology 02-103 clinical trial indicated that this
cell line derived MGP was able to differentiate between patients who
would experience complete response and those who would have residual
disease after neoadjuvant treatment with the selected agents.
Precision also conducted a parallel study with MD Anderson Cancer
Center, Yale Cancer Center and the University of Virginia. A
Systematic Evaluation of Multi-Gene Predictors for the Pathological
Response of Breast Cancer Patients to Chemotherapy examined 42
breast cancer cell lines by using the ChemoFx in-vitro chemoresponse
test afer treatment with two widely used standard combination
chemotherapies for breast cancer. Two different cell line sets and two
independent prediction methods were used to develop cell line-based
MGPs. The evaluation yielded high prediction performances by these MGPs,
which were also able to predict patient clinical outcomes for
estrogen-receptor (ER)-negative patients, which has proven difficult to
date. Results demonstrate the potential for using the ChemoFx test as a
model system in creating MGPs for stratifying patients' therapeutic
"Multi-gene predictors provide an opportunity for more rapid predictive
and/or prognostic information for these patients as well as a molecular
basis for the use of the ChemoFx assay," says Alan Wells, MD, DMSc. Dr.
Wells is a Thomas Gill Professor of Pathology at the University of
Pittsburgh and was consulted for his expertise in cancer treatment.
About Precision Therapeutics
Precision Therapeutics, a leading life-science company based
in Pittsburgh, Pennsylvania, is dedicated to personalized cancer care.
Precision offers a portfolio of products developed to help guide
physicians and patients with difficult clinical decisions throughout the
cancer care continuum.
Precision's state of the art Comprehensive Tumor Profiling is an
integrated, straightforward approach combining three core platforms of
personalized medicine to capture the total sum of genomic, proteomic and
functional information for each patient's cancer.
Precision's first commercial test, ChemoFx®, is a proprietary
drug response marker which measures an individual's malignant tumor
response to a range of standard therapeutic alternatives under
consideration by a physician. Precision currently receives ChemoFx®
specimens from 271 top medical institutions including 20 of the 21
National Comprehensive Cancer Network (NCCN) Member Institutions, and 8
of the US News and World Report Top 10 Hospitals for Cancer Care. To
date, approximately 80,000 patient specimens have been submitted for
ChemoFx® testing using 105 unique chemotherapy treatments and
For more information, visit: www.precisiontherapeutics.com
[ Back To TMCnet.com's Homepage ]